Joanna Brewer - Feb 20, 2025 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Role
Chief Scientific Officer
Signature
/s/ Joanna Brewer
Stock symbol
ADAP
Transactions as of
Feb 20, 2025
Transactions value $
$0
Form type
4
Date filed
2/20/2025, 05:34 PM
Previous filing
Jan 17, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADAP Option to purchase Ordinary Shares Award $0 +1.61M $0.00 1.61M Feb 20, 2025 Ordinary Shares 1.61M $0.10 Direct F1, F2
transaction ADAP Option to purchase Ordinary Shares Award $0 +1.07M $0.00 1.07M Feb 20, 2025 Ordinary Shares 1.07M $0.00 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2 Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029.
F3 The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4 Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029.